quarter you, And and results progress joining Thank our to year-end Thank of hear call our corporate update. company us fourth everyone. afternoon, fourth for earnings quarter you Pharma. this welcome our XXXX to and Nicole. afternoon Good Lantern about also and
oncology development. is the to genomic at clinical, Pharma data leveraging intelligence, leading response and the learning Lantern the costs, of algorithms, transform edge and artificial drug drug discovery and derisk compress machine timelines, biomarker,
our XXXX, done meaningful and development this drug will extremely taking on year launched an this fraction LP-XXX was traditional that the a our at LP-XXX. time insights We've focused candidates, of of During first-in-human team these driving clinical new to with drug approaches. be them programs
progress those drug future will and patients This that time. drug, data is that to therapy in specifically and potentially of development, will available, the so identification from cancer accelerate of reduced and the can the changing or used benefit with derisk really the where data programs, to best cost diseases there's also respond medicines who life much be reduced
And significantly and save in time, helps believe most Our by of many years more model also develop a in new to indications early time stage later and on where for development, we two where of been fraction many indications, we've discovery for are stage trials. can to more both works and trials, transforming fewer the patients in patients, those less able those stage we literally clinical money likely respond, sharpening focusing parallel. it later than with select that
to able being on focused is platform accomplish Our both.
to cancer. for never And team and this for HARMONIC operations cell lung infrastructure foundation been our a our strengthened endeavor. clinical clinical with our clinical Phase time, X been has team And same has the very trial important sites the the Illinois, non-small in At we've joined US, and locations advancing smokers colleagues have that XX scale New help and five experienced and up trial across clinical Ohio, some program. the highly different over York, including We with California. centers select us Texas, activated now over have
across Across there's never being approximately clinical XXXX in potential representing this annual first of monitored to is bolster in pre-screened cancer for XX with will are be activated sites, being be are enrollment. and billion trial potential $X.X and US, the also to anticipated month, that annually, market dosed non-small possible patient Multiple consented to patient XX,XXX expected trials $X already enrollment. smokers, cell the are to five additional the one additional of that later sites lung billion. estimated US just and the XX,XXX are and half diagnosed the there US recruitment In patients an
with effort mutations, pathways targeted combination to profiles very burden really This molecular are of use mutation smokers low have our certain tumor to on associated kinase stay opportunity cancer developed continued chemotherapy has largely and LP-XXX scale been non-small the largely tyrosine when shelf. care. responsive standard modeling the understanding in with of in the would the without never This why by cell those those current large and used drug with data in lung and
driven platform. approach transformative We're data proprietary through AI also RADR our using this
either this underserved, uncovers do that We are cancer, accuracy. often tremendous unmet platform with overlooked. or significant Our opportunities opportunities in
XX%. rescue new launching be for We've and trials many we'll that's coming advanced because them trials, to points, Our bringing advance on also prediction them of XXX relying because the months. into entirely candidates only in Phase clinical over X data first-in-human compounds, this and but also drug to algorithms. And success learning we're is both the machine used not XX% to develop
fraction and progress discuss Kishor And molecules, quarters. again, our about how the of months few at and in entering will they the Dave Also, this a new and financials timeline doing our we're will talk the of next exciting the cost on clinic later are today. and some
and can help and data to fundamental that development. algorithms are predict nearly understand, questions as by is that us Our unique mentioned, served AI platform, model XX drug XXX I over oncology billion points
will that over three data to areas. this it for And we goals major in billion year, expect reach Our functionality we enhance our expect XX platform points.
One, ADCs, better and classes, brain there. pretty algorithms permeability predictions BBB best believe small some understand of and will regimens along are predictive drug probably already those a the compounds. of we're third, not generating antibody compound the targeted conjugates, And at blood cost; that features be least; barrier best-in-class, process antibody develop develop molecules far the with ability of but fraction certain safety only the predict of to algorithms antibodies, anti-cancer of and highly combination model specific out we current at of key a of
and our compression programs a LP-XXX. directed believe that talking first-in-human be the portfolio about clinical cancers. ago The of that and candidates LP-XXX blood lethal drug XX tumors, And about new synthetically with allowed to creating development while of molecules to costs drug in grow be XX we're from at with can solid cancers, our our is will range programs have months three We trials, timeline certain LP-XXX us in trials process both largely LP-XXX today.
transforming of many therapies for opportunities to these in life investors expect value potentially and our We create for high cancer patients. programs
by in points called billions exciting, owned of platform analysis Several wholly Starlight have Lantern borne a focused together brought data new, using and of of The the Pharma's subsidiary Therapeutics. RADR. these were we oncology Starlight being program very by programs from developed AI is
San done anti-tumor make a at in Children's synthetic advanced focused it powerful Center STAR-XXX's recognized we've Hopkins Cancer with clinical and CNS Antonio, therapies coupled collaborations and Greehey the Health institutions UT pathway. mechanism, lethality, that positioned with including rapidly well efficient development to targeted internationally the these
will Starlight starting to in upon seven intends Again, we've the Pharma. late indications. quite IND studies be conducted Lantern Xa testing by rapidly clinical the clinical human CNS to multiple upcoming XXXX. trials It'll pursue from indications, prior enabling gone one Phase and now for build that
development in of be cancers CNS beyond STAR-XXX the trial conducted clinical Starlight. will Phase by Xa exclusively The
Following Center, for as triple Starlight. provide bladder cancer indications advance LP-XXX partnered and development We'll solid continue non-CNS other also to deficiencies. computational breast cancer, we've DDR with clinical biology AI where continue Pharma bioinformatics negative Fox that will in to Starlight, the have launch Cancer Chase tumors indications, support of such pancreatic and Lantern to
or our as progress for what to a efforts the owned trials focus We'll wholly accelerate advancing additional also developed allows is development, manner. the clinical creating Therapeutics, subsidiary for certain and to assets cancer think that our opportunities in community through unique and meaningful CNS resources We upside Starlight for needs looking our sharpen the STAR-XXX Lantern by a of of in personnel deepen while targeted drug time, we patients always patient by and CNS the separated on focus of can programs be the can candidates formation and we to be focusing additional promising The commitment decades. potential for and one where believe investors. dedicate Starlight increased focused most cancer
collaborative Our grow. continues also to portfolio
management with really on TTC-XXX focused They addition the case positive unmet develop our breast currency. our with right a to the as any cancer. In a cancer an emerging it. as of focused biotech and collaboration, they that's collaboration this develops. drug quarters then earlier this breast certain collaborative collaboration we and it in needs we Oncology, program a on develop exclusive we intellectual to started the And you'll the the called is TTC to ER hear ability have platform about and coming team license where the Actuate, year to an And have exciting work in may patients. real is this best-in-class have get drug property more This
insights evolve many to initial candidates continuing our for Lantern the in advancements progress major turning clinical in and into and to and patients observations Pharma as mature human them of potentially trials. make a high value clinical platform, cancer the itself drug labs advance breakthrough of insights by we generated driven meaningful programs. has significant AI our entered validated into We're and transformation period now and
and is driven a developed space. level highly by But burn both programs this at have Lantern platform. our growing at AI almost of unheard that indications and of has span cash Our in Starlight been multiple been it and attractive resourcing
expect as these would with programs companies partner many of We larger develop. they biopharma
LP-XXX an also and webinars, we'll be drug as on candidates, feature Zoltan as which a will the hosting principal And at at expert insight both MD, in and providing joint Children's our who XXX. synthetic Center, one recognized webinar Harvard market School sites, will That an Pediatrics affiliate. Assistant Research Lantern's and through The be the an of LP-XXX, investigator of mechanism Professor internationally KOL of Danish transparency Cancer serves Hospital, a a Boston tomorrow, continuing key lethality, collaborative webinar Medical synthetic Tuesday. appointments our educating focus lethality, Szallasi. webinar He's is and
found on link has release website our be and can Additional earnings details webinar our and of provided in the KOL slides. also been the
We on of to Scientific expect will our for in implications additional up our webinar what lethality, Kishor be and therapy. XXX programs follow in April. with Chief Dr. for another the terms on the this This own by mono are late combination and Bhatia, Officer, led both specifically synthetic webinar
overview, and some also walk call our of David I'll to to David? overview that over items. and our the fourth you an through CFO, housekeeping now results With provide basic quarter turn Margrave, year-end
